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 Transition Metal-Catalyzed Coupling Reactions 
1.1 Introduction 
 The past 40 years have seen major developments in the area of homogenous transition 
metal catalysis for the formation of C–C and carbon–heteroatom bonds. This growth has enabled 
coupling of aryl halides with numerous nucleophiles, including organotin compounds, alkynes, 
organozinc compounds, organosilicon compounds, boronic acids, olefins, and amines or alcohols. 
The significance of this type of chemistry was recognized in 2010, when the Nobel Prize in 
Chemistry was awarded jointly to Richard F. Heck,1 Ei-ichi Negishi,2 and Akira Suzuki3 for their 




 Each of the above reactions proceeds through a series of basic organometallic 
mechanistic steps: oxidative addition of an aryl or alkenyl halide to palladium (0), followed by 
either transmetallation or olefin insertion, and termination by either C–C bond-forming reductive 
a) Heck Reaction





















elimination or β-hydride elimination. A related transformation is the Buchwald-Hartwig 
amination, in which an amine is coupled with an aryl halide using a palladium catalyst (eq. 4).4 
 
The conceptual simplicity of these reactions has resulted in many studies in which the 
coupling partner or composition of the metal catalyst can be optimized depending on the 
substrate. In particular, recent developments in this field have focused on the preparation of new 
ligands to enable general palladium-catalyzed cross-coupling conditions.5 Additionally, the use 
of organometallic chemistry is a promising venue for the synthesis of medicinally relevant 
heterocycles in a highly stereoselective and convergent manner. As such, our group became 
interested in the potential of coupling γ-aminoalkenes with aryl or alkenyl halides. 
1.2 Pd-Catalyzed Alkene Difunctionalization Reactions 
 Over the past several years, our group has developed a methodology for the formation of 
five-membered N-heterocycles,6 wherein the coupling of a γ-aminoalkene with an aryl or alkenyl 
halide is accomplished using a palladium catalyst system and a stoichiometric quantity of base. 
The heterocyclic products can be prepared in good yields with high levels of stereoselectivity; 
notably, these alkene difunctionalization reactions simultaneously form adjacent C–C and C–N 
bonds with high levels of stereoselectivity, as well as up to two stereocenters. We have 
successfully prepared N-protected pyrrolidines,7a-c imidazolidin-2-ones,7d isoxazolidines,7e and 
pyrazolidines7f using this chemistry (Scheme 1). Additionally, we have reported tandem N-
arylation/carboamination reactions (eq. 5) through in situ modification of the palladium 
d) Buchwald-Hartwig Reaction









catalyst.7g Of note, these reactions constitute rare examples of syn-insertion of an alkene into a 
Pd–N bond. 
Scheme 1. Scope of Pd-Catalyzed Carboamination Reaction 
 
 
 The general mechanism for this transformation is shown below (Scheme 2). The catalytic 
cycle is initiated by oxidative addition of the aryl bromide to Pd(0), followed by deprotonation 
and coordination with alkenylamine I-3 to give palladium amido complex I-4. Syn-
aminopalladiation providess intermediate I-5, which undergoes C–C bond-forming reductive 
elimination to give pyrrolidine I-6.8 Evidence for syn-insertion of the alkene into the Pd–N bond 









































Scheme 2. Mechanism of Pyrrolidine Formation via Pd-Catalyzed Carboamination 
 
1.3 Related Alkene Difunctionalization Reactions 
 In addition to our work on Pd-catalyzed carboamination reactions, other groups have 
developed similar methodologies. In early 2010, Oshima and co-workers reported a synthetic 
route to substituted aziridines using a Pd-catalyzed carboamination reaction similar to our own 
(eq. 7).9 Zhang and Toste reported gold-catalyzed carboamination reactions with aryl boronic 
acids using Selectfluor as an oxidant (eq. 8).10 In contrast to the Pd-catalyzed carboamination 
reaction, the gold-catalyzed variant proceeds through anti-addition of the nucleophile and arene 
across the olefin. Additionally, Chemler has reported several examples of intramolecular Cu-


















































1.4 Project Goals 
 The research described in this thesis aims to address several limitations of the Pd-
catalyzed carboamination reaction. Chapter 2 will describe the synthesis of cis-3,5-disubstituted 
morpholines. Chapter 3 will focus on the development of conditions for the synthesis of 
substituted pyrrolidines and other heterocycles using inexpensive aryl chlorides as electrophiles. 
Chapter 4 will describe a catalytic asymmetric synthesis of the natural product (+)-aphanorphine 













New Strategy for the Synthesis of Substituted Morpholines 
2.1 Introduction 
 In recent years, drug discovery efforts have revealed several interesting biologically 
active compounds that contain C-substituted morpholine units. 12 , 13  Despite the medicinal 
importance of these molecules, the development of new approaches to their synthesis remains 
relatively unexplored.12,14 For example, few methods allow the preparation of 3,5-disubstituted 
morpholines,15 and only two approaches to the stereoselective synthesis of cis-3,5-disubstituted 
derivatives have been described.13a,16 Both of these strategies are limited in scope, as one affords 
symmetrically disubstituted (meso) products,16 and the other was used only for the generation of 
one single compound (cis-3-carbomethoxy-5-allylmorpholine).13a 
2.2 Synthesis of cis-3,5-Disubstituted Morpholines 
We recently reported a concise asymmetric synthesis of cis-2,6-disubstituted piperazines 
that involves Pd-catalyzed carboamination reactions of N-allyl ethylenediamine derivatives.17 As 
highlighted in Equation 10, a number of N-allyl ethylenediamines can be converted to cis-2,6-
disubstituted piperazines in moderate to good yields with excellent diastereoselectivity. 
 
We felt that a similar strategy would be applicable to the construction of 3,5-disubstituted 
morpholines. As shown in Equation 11, enantiopure N-Boc amino alcohols (II-1) could be 
converted to O-allyl ethanolamines II-2 using standard methods. These compounds would then 
















alkenyl halide. This modular synthetic strategy should provide access to a broad array of 
enantiopure cis-3,5-disubstituted morpholines that are difficult to generate using existing 
methods. 
 
Treatment of Boc-protected amino alcohols II-1 with NaH and allyl bromide afforded the 
corresponding allyl ethers. Cleavage of the Boc group with TFA followed by Pd–catalyzed N-
arylation of the resulting amine trifluoroacetate salts provided substrates II-2. The use of a 
catalyst composed of Pd(OAc)2 and P(2-furyl)3 afforded morpholines II-3. Representative 
examples of experiments conducted by Matthew Leathen, my graduate student mentor in the 
Wolfe group, are shown below in Table 1. Several O-allylethanolamines were effectively 
converted to the desired products, including heretoatom-containing substrates (Table 1, entries 3 
and 4). Significantly, while the yields are modest, the diastereoselectivities are universally high 






















Table 1. Synthesis of cis-3,5-Disubstituted Morpholinesa. 
 
2.3 Synthesis of Bicyclic Morpholines 
To further explore the utility of this method for the synthesis of other substituted 
morpholines, I examined reactions of several N-aryl ethanolamine derivatives with different 
substitution patterns. As shown in Scheme 3, substrates II-4 through II-7 were prepared by O-






2 mol % Pd(OAc)2
8 mol % P(2-furyl)3










































a Conditions: 1.0 equiv substrate, 2.0 equiv R1Br, 2.0 equiv NaOtBu, 2 mol %
Pd(OAc)2, 8 mol % P(2-furyl)3, toluene (0.4 M), 105 °C. b Isolated Yield (average 
of two experiments).
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Scheme 3. Synthesis of Substrates. 
 
 These substrates were coupled with aryl bromides using our optimized reaction 
conditions as shown in Table 2. These transformations afforded the desired bicyclic morpholines 
in moderate to good yields with excellent diastereoselectivities (> 20:1 d.r.). Of note, the 
carboamination reaction of electron-deficient aryl bromide 4-bromobenzophenone was 
successful with both substrates II-4 and II-6 (Table 2, entries 2 and 4). 
The mechanism of the morpholine-forming carboamination reactions is likely similar to 
that of related transformations that generate piperazines, pyrrolidines, and other nitrogen-
containing heterocycles. As shown in Scheme 4, the key intermediate in the conversion of II-2 to 
II-3 is palladium(aryl)(amido) complex II-8, which is produced by oxidative addition of the aryl 
bromide to Pd(0) followed by Pd–N bond formation. The relative stereochemistry of the 
substituted morpholine products is most consistent with a pathway involving syn-
aminopalladation of II-8 through a boat-like transition state (II-9) to afford II-10 as shown in 
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n = 1, II-6
n = 2, II-7
77-81% 77-99%
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morpholine products II-3. ß-hydride elimination from II-10 followed by Heck arylation would 
result in deleterious 3,4-dihydro-2H-1,4-oxazines observed in crude reaction mixtures.20 This 
mechanism also accounts for the conversion and stereochemical outcome of the bicyclic 
morpholines shown in Table 2. 






2 mol % Pd(OAc)2
8 mol % P(2-furyl)3


























a Conditions: 1.0 equiv substrate, 2.0 equiv R1Br, 2.0-2.7 equiv NaOtBu, 2 mol %
















Scheme 4. Transition State Leading to 3,5-disubstituted Morpholines. 
 
2.4 Conclusions 
In conclusion, a concise asymmetric synthesis of cis-3,5-disubstituted morpholines from 
readily available enantiopure amino alcohol precursors has been described.21 The modular nature 
of this approach permits variation of the morpholine substituents and also provides access to 
fused-ring morpholine derivatives. The strategies described above significantly expand the range 























2.5 Experimental Section 
General:  All reactions were carried out under a nitrogen atmosphere in oven- or flame-dried 
glassware. Palladium (II) acetate and all phosphine ligands were purchased from Strem Chemical 
Co. and used without further purification. All aryl bromides were obtained from commercial 
sources (Aldrich Chemical Co. or Acros Chemical Co.) and were used as obtained. (±)-trans-2-
(Phenylamino)cyclohexanol22 and (±)-trans-(phenylamino)cyclopentanol23 were synthesized via 
ring-opening cyclohexene oxide or cyclopentene oxide with aniline. Toluene and THF were 
purified using a GlassContour solvent purification system. Yields refer to isolated yields of 
compounds estimated to be ≥95% pure as determined by 1H NMR and either capillary GC 
(known compounds) or ESI Mass Spectrometry (new compounds). The yields reported in this 
section describe the result of a single experiment, whereas the yields reported in Table 1 and 
Table 2 are average yields of two or more experiments. Thus, the yields reported in this section 
may differ from those shown in Table 1 and Table 2. 
Synthesis of Substrates 
 
(±)-(1S*,2S*)-N-(2-Hydroxycyclohexyl)-N-phenylbenzamide (II-S1). A solution of (±)-trans-
2-(phenylamino)cyclohexanol22 (956 mg, 5.0 mmol) and triethylamine (2.1 mL, 15 mmol), in 
dichloromethane (10 mL), was cooled to 0 °C, and benzoyl chloride (0.6 mL, 4.9 mmol) was 
added dropwise. The reaction mixture was warmed to room temperature, stirred for 48 h, and 
transferred to a separatory funnel. The mixture was washed with 2 M HCl (2 x 10 mL) and 







anhydrous Na2SO4, filtered and concentrated in vacuo. The crude material was purified by flash 
chromatography on silica gel using 2.5% MeOH/dichloromethane as the eluent to afford 1.13 g 
(77%) of the title compound as a white solid, m.p. 182–184 °C. 1H NMR (400 MHz, CDCl3) d 
7.30–7.24 (m, 2 H), 7.24–7.06 (m, 8 H), 4.77–4.61 (m, 1 H), 3.53–3.37 (m, 1 H), 2.76 (s, br, 1 
H), 2.12 (d, J = 12.0 Hz, 1 H), 2.01–1.89 (m, 1 H), 1.78–1.63 (m, 2 H), 1.52–1.29 (m, 2 H), 
1.29–1.00 (m, 2 H); 13C NMR (100 MHz, CDCl3) d 173.2, 139.5, 136.8, 130.8, 129.1, 128.7, 
128.3, 127.63, 127.56, 71.7, 61.5, 35.7, 30.2, 25.2, 24.3; IR (film) 3319, 1622, cm-1; MS (ESI) 
318.1465 (318.1470 calcd for C19H21NO2 M + Na+). 
 
(±)-cis-2-(Phenylamino)cyclohexanol (II-S2). A solution of II-S1 (3.0 g, 10.2 mmol) in 
dichloromethane (50 mL) under nitrogen was cooled to 0 °C and thionyl chloride (4.4 mL, 61 
mmol) was added. The reaction mixture was warmed to room temperature and stirred overnight. 
The reaction mixture was then concentrated in vacuo, and 6 N HCl (50 mL) was added. The 
resulting mixture was heated to reflux with vigorous stirring for 6 h, then was cooled to rt, 
filtered, and the aqueous phase was extracted with EtOAc (3 x 50 mL). The combined ethyl 
acetate layers were discarded, and the aqueous layer was basified to pH > 9 using 5 M NaOH. 
The aqueous layer was then extracted with ether (3 x 50 mL), and the combined ether layers 
were dried over anhydrous Na2SO4, filtered, and concentrated in vacuo. The crude product was 
purified by flash chromatography on silica gel using 15% EtOAc/hexanes as the eluent to afford 
1.5 g (77%) of the title compound as a white solid, m.p. 75–77 °C (lit.24 m.p. 72–74 °C). 1H 
NMR (400 MHz, CDCl3) d 7.24–7.17 (m, 2 H), 6.79–6.72 (m, 1 H), 6.68 (dd, J = 1.0, 7.8 Hz, 2 







H), 1.76–1.56 (m, 5 H), 1.52–1.28 (m, 2 H); 13C NMR (100 MHz, CDCl3) d 147.2, 129.2, 117.6, 
113.7, 67.6, 54.8, 31.3, 27.0, 23.5, 20.0; IR (film) 3397, 1505 cm–1; MS (ESI) 214.1211 
(214.1208 calcd for C12H17NO, M + Na+). 
 
(±)-(1S*,2S*)-N-(2-Hydroxycyclopentyl)-N-phenylbenzamide (II-S3). A solution of (±)-
trans-2-(phenylamino)cyclopentanol23 (1.78 g, 10 mmol) and triethylamine (8.4 mL, 60 mmol) 
in dichloromethane (20 mL), was cooled to 0 °C with stirring and benzoyl chloride (3.5 mL, 30 
mmol) was added dropwise.  The reaction mixture was warmed to room temperature and stirred 
overnight. The mixture was transferred to a separatory funnel, washed with 2 M HCl (2 x 10 mL) 
and extracted with dichloromethane (3 x 20 mL). The combined organic layers were dried over 
anhydrous Na2SO4, filtered and concentrated in vacuo. The resulting oil was dissolved in 
methanol (25 mL), and potassium carbonate (6.9 g, 50 mmol) was added slowly at room 
temperature. The reaction mixture was stirred at room temperature for 48 hours, and the reaction 
was quenched with saturated ammonium chloride (25 mL). The mixture was transferred to a 
separatory funnel and extracted with CH2Cl2 (3 x 25 mL). The combined organic layers were 
dried over anhydrous Na2SO4, filtered, and concentrated in vacuo to give a red-orange oil. The 
crude material was dissolved in a minimal amount of hot ethyl acetate and cooled in a –20 °C 
freezer until crystals formed. Filtration afforded 2.27 g (81%) of the title compound as a white 
solid, mp 109–113 °C.  1H NMR (400 MHz, CDCl3) d 7.30–7.03 (m, 10 H), 4.79–4.69 (m, 1 H), 
4.28–4.18 (m, 1 H), 4.02 (s, br, 1 H), 1.97–1.86 (m, 2 H), 1.82–1.63 (m, 2 H), 1.61–1.50 (m, 1 







128.3, 127.64, 127.57, 76.8, 67.5, 32.5, 28.4, 21.0; IR (film) 3401, 1633 cm–1; MS (ESI) 
304.1312 (304.1313 calcd for C18H19NO2, M + Na+). 
 
(±)-cis-2-(Phenylamino)cyclopentanol (II-S4).  The conversion of II-S3 (1.41 g, 5.0 mmol) to 
the title compound was accomplished using a procedure analogous to that described above for 
the synthesis of S2. This procedure afforded 880 mg (99%) of the title compound as a clear and 
colorless oil. 1H NMR (400 MHz, CDCl3) d 7.23–7.14 (m, 2 H), 6.81–6.61 (m, 3 H), 4.33–4.23 
(m, 1 H), 3.69–3.53 (m, 1 H), 3.05 (s, br, 1 H), 2.17–2.01 (m, 1 H), 2.00–1.75 (m, 3 H), 1.69–
1.49 (m, 2 H) (the OH signal was not observed due to broadening); 13C NMR (100 MHz, CDCl3) 
d 147.7, 129.3, 118.1, 113.5, 71.3, 59.4, 32.5, 30.1, 20.3; IR (film) 3398, 1504 cm–1; MS (ESI) 
178.1225 (178.1232 calcd for C11H15NO M + H+). 
 
trans-2-(Allyloxy)cyclopentylaniline (II-4). The conversion of trans-2-
(phenylamino)cyclopentanol23. (500 mg, 2.82 mmol) to the title compound was accomplished 
using a procedure analogous to that described above for the synthesis of II-7. This procedure 
afforded 535 mg (87%) of the title compound as an amber oil. 1H NMR (400 MHz, CDCl3) d 
7.19–7.10 (m, 2 H), 6.71–6.57 (m, 3 H), 5.98–5.83 (m, 1 H), 5.26 (dd, J = 1.6, 17.2 Hz, 1 H), 
5.13 (d, J = 10.0 Hz, 1 H), 4.04–3.89 (m, 2 H), 3.74–3.65 (m, 2 H), 3.48 (s, br, 1 H), 2.25–2.10 












129.0, 117.0, 116.4, 113.0, 84.9, 69.9, 59.8, 31.5, 30.0, 21.7; IR (film) 3404 cm–1; MS (ESI) 
218.1543 (218.1545 calcd for C14H19NO, M + H+). 
 
trans-2-(Allyloxy)cyclohexylaniline (II-5). The conversion of trans-2-
(phenylamino)cyclohexanol10 (500 mg, 2.62 mmol) to the title compound was accomplished 
using a procedure analogous to that described above for the synthesis of II-7. This procedure 
afforded 578 mg (95%) of the title compound as an amber oil. Spectroscopic properties were 
consistent with those reported in the literature.  
 
cis-2-(Allyloxy)cyclopentylaniline (II-6). The conversion of II-6 (532 mg, 3 mmol) was 
accomplished using a procedure analogous to that described above for the synthesis of II-7. This 
procedure afforded 601 mg (92%) of the title compound as an amber oil. 1H NMR (400 MHz, 
CDCl3) d 7.19–7.13 (m, 2 H), 6.70–6.59 (m, 3 H), 5.95–5.82 (m, 1 H), 5.26 (dq, J = 1.6, 15.3 Hz, 
1 H), 5.15 (dq, J = 1.5, 9.0 Hz, 1 H), 4.34 (s, br, 1 H), 4.05–3.98 (m, 1 H), 3.96–3.89 (m, 2 H), 
3.75–3.65 (m, 1 H), 2.07–1.94 (m, 1 H), 1.88–1.76 (m, 3 H), 1.71–1.51 (m, 2 H); 13C NMR (100 
MHz, CDCl3) d 148.0, 135.0, 129.2, 116.9, 116.7, 113.3, 79.9, 70.3, 56.1, 29.8, 29.4, 20.3; IR 


















cis-2-(Allyloxy)cyclohexylaniline  (II-7). A solution of II-S2 (764 mg, 4.0 mmol) in THF (16 
mL) cooled to 0 °C under nitrogen with stirring. Solid NaH (216 mg, 5.6 mmol, 60% suspension 
in mineral oil) was added slowly, and the resulting mixture was stirred for 30 minutes at 0 °C. 
Allyl bromide (0.4 mL, 4.4 mmol) was added, and the mixture was warmed to room temperature. 
After the starting material had been completely consumed as judged by TLC analysis, the 
reaction was quenched with saturated aqueous NH4Cl and transferred to a separatory funnel. The 
mixture was extracted with EtOAc (3 x 15 mL), and the combined organic layers were washed 
with brine, dried over anhydrous Na2SO4, filtered and concentrated in vacuo. The crude product 
was purified by flash chromatography on silica gel using 2% EtOAc/hexanes as the eluent to 
afford 610 mg (66%) of the title compound as an amber oil.  1H NMR (400 MHz, CDCl3) d 
7.20–7.13 (m, 2 H), 6.70–6.60 (m, 3 H), 5.98–5.86 (m, 1 H), 5.31–5.24 (m, 1 H), 5.17–5.12 (m, 
1 H), 4.16–4.03 (m, 2 H), 3.93–3.86 (m, 1 H), 3.71–3.66 (m, 1 H), 3.45–3.37 (m, 1 H), 2.05–1.97 
(m, 1 H), 1.81–1.68 (m, 2 H), 1.67–1.50 (m, 2 H), 1.48–1.26 (m, 3 H); 13C NMR (100 MHz, 
CDCl3) d 147.4, 135.4, 129.2, 117.0, 116.2, 113.6, 75.5, 69.6, 53.7, 28.3, 27.4, 24.2, 20.2; IR 
(film) 3402, 1505 cm–1; MS (ESI) 232.1707 (232.1701 calcd for C15H21NO, M + H+). 
General Procedure 1: Synthesis of Morpholines via Pd-Catalyzed Carboamination. A Schlenk 
tube was evacuated, flame dried and backfilled with nitrogen. The tube was charged with 
Pd(OAc)2 (2.3 mg, 0.01 mmol), P(2-furyl)3 (9.3 mg, 0.04 mmol), and NaOtBu (96.1 mg, 1.0 
mmol). The tube was evacuated and backfilled with nitrogen, then the aryl bromide (1.0 mmol) 
and a solution of the amine substrate (0.50 mmol) in toluene (1.25 mL) were added to the 
Schlenk tube (aryl bromides that were solids at room temperature were added as solids following 
the addition of NaOtBu). The mixture was heated to 105 °C with stirring until the substrate was 
consumed as judged by GC analysis (ca. 22 h). The reaction mixture was cooled to room 
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temperature, saturated aqueous NH4Cl (3 mL) was added, and the mixture was extracted with 
EtOAc (3 x 3 mL). The combined organic layers were concentrated in vacuo and the crude 
product was purified by flash chromatography on silica gel. 
 
(±)-(3R*,4aS*,8aR*)-3-Benzyl-4-phenyloctahydro-2H-benzo[b][1,4]oxazine. General 
Procedure 1 was employed for the coupling of bromobenzene with II-7 (174 mg, 0.75 mmol). 
This procedure gave the title compound (150 mg, 65%) as white solid after purification by 
chromatography with 2% EtOAc/hexanes as the eluent. This material was judged to be of >20:1 
d.r. by 1H NMR analysis before and after purification. m.p. 96–98 °C; 1H NMR (400 MHz, 
CDCl3) d 7.38–7.28 (m, 6 H), 7.26–7.20 (m, 1 H), 6.93–6.83 (m, 2 H), 6.79–6.71 (m, 1 H), 4.04 
(d, J = 12.0 Hz, 1 H), 3.73–3.53 (m, 4 H), 3.05 (t, J = 12.0 Hz, 1 H), 2.80 (d, J = 13.0 Hz, 1 H), 
2.08 (d, J = 14.0 Hz, 1 H), 1.95 (d, J = 12.0 Hz, 1 H), 1.86–1.49 (m, 5 H), 1.34–1.20 (m, 1 H); 
13C NMR (100 MHz, CDCl3) d 146.5, 139.9, 129.6, 129.3, 128.7, 126.3, 116.6, 111.8, 75.6, 67.8, 
53.0, 37.2, 31.7, 25.4, 25.0, 20.9 (one aliphatic carbon signal is absent due to incidental 




Procedure 1 was employed for the coupling of bromobenzene with II-5 (174 mg, 0.75 mmol). 
This procedure gave the title compound (126 mg, 55%) as a white crystalline solid, after 








to be of >20:1 d.r. by 1H NMR analysis before and after purification. m.p. 128–130 °C;1H NMR 
(400 MHz, CDCl3) d 7.40–7.08 (m, 8 H), 6.99–6.91 (m, 2 H), 3.78 (d, J = 11.3 Hz, 1 H), 3.48 (t, 
J = 10.3 Hz, 1 H), 3.37–3.24 (m, 2 H), 2.56 (d, J = 13.0 Hz, 2 H), 2.21–2.09 (t, J = 11.7 Hz, 1 H), 
1.92 (d, J = 10.3 Hz, 1 H), 1.68 (d, J = 10.3 Hz, 1 H), 1.54 (d, J = 11.7 Hz, 1 H), 1.42–1.20 (m, 3 
H), 1.16–0.94 (m, 2 H); 13C NMR (100 MHz, CDCl3) d 148.7, 138.5, 129.1, 128.9, 128.2, 128.0, 
126.3, 126.1, 80.8, 71.7, 66.6, 62.5, 37.5, 31.3, 29.7, 24.6, 24.5; IR (film) 1488, 1448 cm–1; MS 
(ESI) 308.2018 (308.2014 calcd for C21H25NO, M + H+). 
 
(±)-(3R*,4aS*,7aS*)-3-Benzyl-4-phenyloctahydrocyclopenta[b][1,4]oxazine. General 
Procedure 1 was employed for the coupling of bromobenzene with II-4 (54 mg, 0.25 mmol). 
This procedure gave the title compound (52 mg, 71%) as yellow solid after purification by 
chromatography with 15% EtOAc/hexanes as the eluent. This material was judged to be of >20:1 
d.r. by 1H NMR analysis before and after purification. m.p. 84–86 °C; 1H NMR (400 MHz, 
CDCl3) d 7.39–7.33 (m, 2 H), 7.30–7.26 (m, 2 H), 7.24–7.28 (m, 3 H), 7.17–7.12 (m, 1 H), 7.04–
7.00 (m, 2 H), 3.87 (dd, J = 3.1, 8.2 Hz, 1 H), 3.59–3.47 (m, 2 H), 3.30 (tt, J = 3.6, 10.1 Hz, 1 H), 
2.75–2.63 (m, 2 H), 2.23 (dd, J = 3.8, 10.2 Hz, 1 H), 1.98–1.89 (m, 1 H), 1.69–1.52 (m, 3 H), 
1.37–1.29 (m, 2 H); 13C NMR (100 MHz, CDCl3) d 149.2, 138.6, 129.0, 128.9, 128.3, 126.5, 
126.2, 126.0, 82.9, 72.8, 68.7, 61.8, 36.6, 26.7, 26.2, 17.4; IR (film) 1597, 1492, 1126 cm–1; MS 











ylmethyl)phenyl ketone. General Procedure 1 was employed for the coupling of 4-
bromobenzophenone with II-4 (163 mg, 0.75 mmol). This procedure gave the title compound 
(151 mg, 51%) as yellow solid after purification by chromatography with 15% EtOAc/hexanes 
as the eluent followed by heating under vacuum in a Kugelrohr apparatus (180 °C, 0.3 Torr) to 
remove hydrocarbon impurities. This material was judged to be of >20:1 d.r. by 1H NMR 
analysis before and after purification. m.p. 84–86 °C;1H NMR (400 MHz, CDCl3) d 7.78–7.74 
(m, 2 H), 7.69–7.65 (m, 2 H), 7.60–7.54 (m, 1 H), 7.49–7.44 (m, 2 H), 7.40–7.34 (m, 2 H), 7.30–
7.25 (m, 2 H), 7.24–7.19 (m, 1 H), 7.15–7.10 (m, 2 H), 3.88 (dd, J = 3.3, 8.0 Hz, 1 H), 3.61–3.48 
(m, 2 H), 3.40–3.31 (m, 1 H), 2.81–2.65 (m, 2 H), 2.37 (dd, J = 4.0, 10.0 Hz, 1 H), 2.00–1.89 (m, 
1 H), 1.70–1.56 (m, 3 H), 1.38–1.29 (m, 2 H); 13C NMR (100 MHz, CDCl3) d 196.3, 149.1, 
143.8, 137.7, 135.6, 132.3, 130.3, 129.9, 129.1, 128.8, 128.2, 126.5, 126.1, 82.9, 72.7, 68.6, 61.6, 
36.7, 26.6, 26.2, 17.4; IR (film) 1658, 1606 cm–1; MS (ESI) 398.2119 (398.2120 calcd for 
C27H27NO2, M + H+). 
 
(±)-(3R*,4aS*,7aR*)-Phenyl 4-(4-phenyloctahydrocyclopenta[b][1,4]oxazin-3-
ylmethyl)phenyl ketone. General Procedure 1 was employed for the coupling of 4-
bromobenzophenone with II-6 (109 mg, 0.5 mmol). This procedure gave the title compound 
(150 mg, 75%) as yellow oil after purification by chromatography with 10% EtOAc/hexanes as 
the eluent followed by heating under vacuum in a Kugelrohr apparatus (160 °C, 0.3 Torr) to 
remove hydrocarbon impurities. This material was judged to be of >20:1 d.r. by 1H NMR 






7.56 (m, 1 H), 7.52–7.45 (m, 2 H), 7.44–7.40 (m, 2 H), 7.37–7.30 (m, 2 H), 6.91 (d, J = 8.3 Hz, 2 
H), 6.79 (t, J = 7.0 Hz, 1 H), 4.01–3.96 (m, 1 H), 3.89 (d, J = 11.6 Hz, 1 H), 3.83–3.68 (m, 2 H), 
3.58–3.50 (m, 1 H), 3.11 (dd, J = 1.2, 13.0, 1 H), 2.95 (d, J = 13.0, 1 H), 2.38–2.25 (m, 1 H), 
2.12–1.86 (m, 3 H), 1.74–1.50 (m, 2 H); 13C NMR (100 MHz, CDCl3) d 196.3, 147.1, 144.7, 
137.7, 135.8, 132.3, 130.6, 130.0, 129.6, 129.3, 128.3, 116.9, 111.9, 78.2, 66.0, 56.3, 52.7, 35.6, 
31.3, 28.1, 21.6; IR (film) 1658, 1597 cm–1; MS (ESI) 420.1925 (420.1939 calcd for C27H27NO2, 
M + Na+). 
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Chapter 3 
Use of Aryl Chlorides as Electrophiles in Pd-Catalyzed Alkene Difunctionalization 
Reactions 
3.1 Introduction 
 Typically, aryl bromides have been employed as the electrophiles in Pd-catalyzed 
carboamination reactions. In order to expand the scope and utility of this chemistry, we felt it 
would be useful to investigate conditions under which similar products could be generated using 
analogous aryl chlorides as cross-coupling partners, in large part due to the significant economic 
benefits associated with aryl chlorides relative to aryl bromides. In our prior studies, we had 
found that chelating phosphine ligands with wide bite angles, such as DPEphos, Xantphos, or 
dppb, provided optimal results in many transformations of aryl bromides.25 However, palladium 
catalysts supported by these ligands are not sufficiently active to facilitate transformations of aryl 
chlorides as electrophiles, which are considerably less reactive than the corresponding aryl 
bromides. Thus, to achieve our goal, we would need to discover catalysts that both activate aryl 
chlorides, and also promote the alkene carboamination process.26 
3.2 Optimization Studies 
 Earlier research in our group demonstrated that a catalyst composed of Pd2(dba)3 and 
PCy2Ph was useful for the preparation of N-aryl pyrrolidines via carboamination reactions with 
aryl chlorides (eq. 11).27 Use of this ligand, however, also led to the formation of small amounts 











 The mechanism of the carboamination reaction involves syn-aminopalladation of 
intermediate A, followed by C–C bond-forming reductive elimination from intermediate B to 
give pyrrolidine product C (Scheme 5). Arylated product D results from competing C–N bond-
forming reductive elimination of intermediate A.28 Undesired regioisomers F can be generated 
through ß-hydrogen elimination of intermediate B followed by a series of hydridopalladation/ß-
hydride elimination steps. 
Scheme 5. Mechanism of Pyrrolidine and Side Product Formation 
 
Our mechanistic analysis suggests that transformations of the analogous N-Boc protected 







































rate of C–N bond-forming reductive elimination that leads to N-arylation.29 We felt that bulky 
electron-rich ligands could be used to facilitate the C–C bond-forming step to avoid competing 
N-arylation. Additionally, the electron-withdrawing nature of the Boc group also disfavors ß-
hydride elimination pathways that provide regioisomers, which should further aid in the selective 
formation of a single product. 
With these mechanistic considerations in mind, we undertook a ligand screen with 
several ligands known to promote coupling reactions with aryl chlorides (Figure 1). The only 
side product observed in crude mixtures was III-2b, which resulted from base-mediated Boc 
cleavage followed by subsequent N-arylation reactions. We were pleased to find the ligand S-
phos provided the desired pyrrolidine III-2a in 69% 1H NMR yield with no formation of III-
2b.30 





2 mol % Pd(OAc)2
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3.3 Scope and Limitations 
In order to explore the scope of this method, we examined the coupling of a range of N-
Boc-protected γ-aminoalkene derivatives. 31  As shown in Table 3, the transformations are 
effective with a variety of aryl chlorides, including electron-rich, electron-poor, and ortho-
substituted compounds. Satisfactory results were also obtained with the heteroaromatic 
electrophiles N-benzyl-5-chloroindole, 2-chloropyridine, and 2-chloropyrazine (to give products 
III-2d, III-2h, and III-2j).32 In all cases, no regioisomeric byproducts were observed in the 
crude reaction mixtures.  
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a Conditions: 1.0 equiv substrate, 1.2 equiv ArBr, 1.2 equiv NaOtBu, 2 mol % Pd(OAc)2, 4 mol % S-phos, 





The synthesis of cis-2,5-disubstituted products was achieved with excellent stereocontrol 
(III-2n and III-2o), and good to excellent selectivity was obtained in the synthesis of trans-2,3-
disubstituted products (III-2k, III-2l and III-2m, Table 4). In all cases the products were 
generated with complete regioselectivity. Efforts to employ substrates bearing internal alkenes 
were unsuccessful due to competing base-mediated substrate decomposition.33 
Table 4. Stereoselective Synthesis of Pyrrolidines.a 
 
 
The stereochemistry of the pyrrolidine products generated in these reactions is likely 
determined in the syn-aminopalladation step of the catalytic cycle shown in Scheme 5. For 
example, substrates bearing allylic substituents are transformed into trans-2,3-disubstituted 
pyrrolidines III-2k, III-2l, and III-2m through the transition state shown in Figure 2. In these 
cases, the R group is oriented in a pseudoequatorial position in order to avoid disfavorable 
diaxial interactions. This transition state also accounts for the increased selectivity observed 
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a Conditions: 1.0 equiv substrate, 1.2 equiv ArBr, 1.2 equiv NaOtBu, 2 mol % Pd(OAc)2, 4 mol % S-phos, 
toluene (0.25 M), 90 °C. b Isolated yield (average of two experiments).
Figure 2. Stereochemical Rationale for 2,3-disubstituted Pyrrolidines. 
  
Cis-2,5-disubstituted pyrrolidines III-2n and III-2o could also be prepared with high 
selectivity through the transition state shown in Figure 3. In this case, the C1-R group is oriented 
in a pseudoaxial position, which avoids A(1,3)-strain between the R group and the nitrogen 
protecting group. 
Figure 3. Stereochemical Rationale for 2,5-disubstituted Pyrrolidines. 
 
  Following our success with N-Boc-aminopropylalkenes, we proceeded to examine the 
utility of the Pd(OAc)2/S-phos catalyst in carboamination and carboetherification reactions of 
aryl chlorides to generate other heterocycles. As shown in Table 5, imidazolidin-2-one III-3, 
isoxazolidine III-4, and pyrazolidine III-5 could be prepared from the corresponding 
alkenylamines. The heterocyclic products were obtained in good chemical yield, and III-4 was 













































although a 13:1 mixture of regioisomers was generated. Unfortunately, attempts to effect a 
similar transformation for the preparation of III-7 were unsuccessful; instead, oxidation of the 
alcohol starting material was observed, which suggests that alkene oxypalladation from an 
intermediate analogous to A is relatively slow with S-phos as a ligand. As a result, ß-hydride 
elimination from this intermediate is the predominant reaction pathway with the secondary 
alcohol substrate. Morpholine product III-8 and its N-Boc analogue could not be prepared due to 
competing N-arylation of the substrate.34 
Table 5. Synthesis of Other Heterocycles Using Aryl Chlorides as Electrophiles.a 
 
 
 3.4 Conclusions 
 In conclusion, we have developed conditions that allow use of inexpensive and readily 
available aryl chloride electrophiles in many Pd-catalyzed carboamination and 






2 mol% Pd(OAc)2 
4 mol % S-phos


































a Conditions: 1.0 equiv substrate, 1.2 equiv ArBr, 1.2 equiv NaOtBu, 2 mol % Pd(OAc)2, 4 mol % S-phos, toluene 
(0.25 M), 90 °C. b Isolated yield (average of two experiments).
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method for heterocycle synthesis and also illustrate several remaining challenges for catalyst 




3.5 Experimental Section 
General: All reactions were carried out under a nitrogen atmosphere in flame-dried glassware. 
Palladium (II) acetate and all phosphine ligands were purchased from Strem Chemical Co. and 
used without further purification. All reagents and aryl chlorides except 1-benzyl-5-chloro-1H-
indole35 were obtained from commercial sources and were used as obtained. N-(pent-4-en-1-
yl)aniline, 36  N-(hex-5-en-2-yl)-4-methoxyaniline,36 4-methoxy-N-(3-phenylpent-4-en-1-
yl)aniline,36 N-[2-(cyclopent-2-en-1-yl)ethyl]aniline,37 tert-butyl pent-4-en-1-ylcarbamate,38 (±)-
tert-butyl (3-methylpent-4-en-1-yl)carbamate,38 1-allyl-1-benzyl-3-(4-methoxyphenyl)urea,39 (±)-
tert-butyl (1-phenylbut-3-en-1-yl)oxycarbamate, 40  tert-butyl 2-(2-methylpent-4-en-2-
yl)hydrazinecarboxylate41 and 2-methylhex-5-en-2-ol42 were prepared according to published 
procedures. The relative stereochemistry of products with two or more stereocenters was 
assigned by comparison of 1H and 13C-NMR spectra to related compounds prepared by Pd-
catalyzed alkene carboamination that have been previously reported in the literature.36–42 Toluene 
and diethyl ether were purified using a GlassContour solvent purification system. The yields 
reported in this section describe the result of a single experiment, whereas the yields reported in 
Tables 3–5 are average yields of two or more experiments. Thus, the yields reported in this 
section may differ from those shown in Table 3–5. 
Synthesis of Substrates 
 
tert-Butyl (2,2-dimethylpent-4-en-1-yl)carbamate.43 To a stirred solution of 2,2-dimethylpent-




(2.02 g, 9.3 mmol). The resulting mixture was stirred until the starting material had been 
consumed as judged by TLC analysis. A solution of 1 M NaOH (ca. 40 mL) was added to the 
system, and the mixture was stirred vigorously overnight. The layers were separated, and the 
aqueous layer was extracted with diethyl ether (3 x 20 mL). The organic layers were combined, 
dried (Na2SO4) and concentrated in vacuo, and the crude product was purified by flash 
chromatography on silica gel to afford 1.60 g (89%) of the title compound as a pale yellow oil. 
1H NMR (400 MHz, CDCl3) δ 5.91–5.74 (m, 1 H), 5.10–4.98 (m, 2 H), 4.56 (s, br, 1 H), 2.95 (d, 
J = 6.4 Hz, 2 H), 1.96 (d, J = 7.4 Hz, 2 H), 1.44 (s, 9 H), 0.67 (s, 6 H). 
 
tert-Butyl [(1-allylcyclohexyl)methyl]carbamate. The conversion of (1-
allylcyclohexyl)methanamine44 (2.17 g, 14.2 mmol) to the title compound was accomplished 
using a procedure analogous to that described above for the synthesis of tert-butyl (2,2-
dimethylpent-4-en-1-yl)carbamate. This procedure afforded 3.52 g (83%) of the title compound 
as a pale yellow oil. 1H NMR (400 MHz, CDCl3) δ 5.88–5.73 (m, 1 H), 5.08–5.00 (m, 2 H), 4.52 
(s, br, 1 H), 3.01 (d, J = 6.3 Hz, 2 H), 2.01 (d, J = 8.4 Hz, 2 H), 1.49–1.33 (m, 15 H), 1.30–1.20 
(m, 4 H); 13C NMR (100 MHz, CDCl3) δ 156.1, 134.7, 117.3, 78.9, 46.9, 40.5, 36.9, 33.2, 28.4, 








tert-Butyl (2,2-diallylpent-4-en-1-yl)carbamate. The conversion of 2,2-diallylpent-4-en-1-
ylamine45 (1.2 g, 7.3 mmol) was accomplished using a procedure analogous to that described 
above for the synthesis of tert-butyl (2,2-dimethylpent-4-en-1-yl)carbamate. This procedure 
afforded 1.5 g (77%) of the title compound as a pale yellow oil. 1H NMR (400 MHz, CDCl3) δ 
5.90–5.71 (m, 3 H), 5.10–4.99 (m, 6 H), 4.63–4.50 (s, br, 1 H), 3.00 (d, J = 6.1 Hz, 2 H), 1.97 (d, 
J = 7.6 Hz, 6 H), 1.40 (s, 9 H); 13C NMR (100 MHz, CDCl3) δ 155.9, 134.0, 117.9, 78.9, 45.9, 
40.1, 39.5, 28.3; IR (film) 3356, 1698, 1638 cm–1; MS (ESI): 288.1934 (288.1939 calcd for 
C16H27NO2, M + Na+). 
 
(±)-tert-Butyl (3-phenylpent-4-en-1-yl)carbamate. The conversion of (±)-3-phenylpent-4-en-1-
ylamine46 (670 mg, 4.2 mmol) was accomplished using a procedure analogous to that described 
above for the synthesis of tert-butyl (2,2-dimethylpent-4-en-1-yl)carbamate. This procedure 
afforded 629 mg (58%) of the title compound as a pale yellow oil. 1H NMR (400 MHz, CDCl3) δ 
7.33–7.27 (m, 2 H), 7.23–7.17 (m, 3 H), 6.01–5.90 (m, 1 H), 5.11–5.02 (m, 2 H), 4.56 (s, br, 1 
H), 3.31 (dd, J = 7.5, 14.9 Hz, 1 H), 3.17–2.99 (m, 2 H), 1.99–1.82 (m, 2 H), 1.44 (s, 9 H); 13C 
NMR (100 MHz, CDCl3) δ 155.8, 143.4, 141.4, 128.5, 127.4, 126.4, 114.5, 79.0, 47.4, 38.9, 35.3, 
28.3; IR (film) 3351, 1699 cm–1; MS (ESI): 284.1625 (284.1626 calcd for C16H23NO2, M + Na+). 
 
(±)-tert-Butyl hex-5-en-2-ylcarbamate. The conversion of (±)-hex-5-en-2-ylamine47 (519 mg, 







synthesis of tert-butyl (2,2-dimethylpent-4-en-1-yl)carbamate. This procedure afforded 776 mg 
(75%) of the title compound as a clear and colorless oil. 1H NMR (400 MHz, CDCl3) δ 5.83–5.67 
(m, 1 H), 5.02–4.85 (m, 2 H), 4.40 (s, br, 1 H), 3.70–3.48 (m, 1 H), 2.03 (dd, J = 7.4, 14.7 Hz, 2 
H), 1.55–1.29 (m, 11 H), 1.05 (dd, J = 2.4, 6.7 Hz, 3 H); 13C NMR (100 MHz, CDCl3) δ 155.2, 
138.0, 114.6, 78.7, 46.0, 36.4, 30.2, 28.3, 21.1; IR (film) 3338, 1683 cm–1; MS (ESI): 222.1469 
(222.1470 calcd for C11H21NO2, M + Na+). 
General Procedure 1: Pd-catalyzed carboamination of γ-N-(Boc)aminoalkenes and related 
nucleophiles. A Schlenk tube was evacuated, flame-dried and backfilled with nitrogen. The tube 
was charged with Pd(OAc)2 (2.3 mg, 0.01 mmol), 2-dicyclohexylphosphino-2’,6’-dimethoxy-
1,1’-biphenyl (S-Phos, 8.2 mg, 0.02 mmol) and NaOtBu (57.7 mg, 0.60 mmol). The tube was 
evacuated and backfilled with nitrogen three times. A solution of the amine substrate (0.50 
mmol) and the aryl chloride (0.60 mmol) in toluene (4 mL/mmol amine substrate) was added to 
the Schlenk tube via syringe (aryl chlorides that were solids are room temperature were added 
neat in one portion following the addition of NaOtBu). The mixture was heated in a 90 °C oil 
bath with stirring until the starting material had been consumed as judged by GC analysis (6–12 
h). The reaction mixture was cooled to room temperature, and saturated aqueous NH4Cl (2 mL) 
and EtOAc (2 mL) were added to the system. The layers were separated, and the aqueous layer 
was extracted with EtOAc (3 x 5 mL). The organic layers were concentrated in vacuo, and the 
crude product was purified by flash chromatography on silica gel. 
 
(±)-tert-Butyl 2-(4-methylbenzyl)pyrrolidine-1-carboxylate (III-2a). General procedure 1 was 




ylcarbamate (93 mg, 0.50 mmol) to afford 95 mg (69%) of the title compound as a pale yellow 
oil. 1H NMR (400 MHz, C6D5CD3, 100 °C) δ 7.03–6.89 (m, 4 H), 4.03–3.91 (m, 1 H), 3.33–3.23 
(m, 1 H), 3.20–3.01 (m, 2 H), 2.51 (dd, J = 8.9, 13.0 Hz, 1 H), 2.13 (s, 3 H), 1.55–1.28 (m, 13 
H); 13C NMR (100 MHz, C6D5CD3, 100 °C) δ 154.6, 137.1, 135.9, 130.0, 129.6, 78.9, 59.5, 59.4, 
47.2, 30.3, 29.1, 23.7, 21.2; IR (film) 1693, 1394, 1172 cm–1; MS (ESI): 298.1779 (298.1783 
calcd for C17H25NO2, M + Na+). 
 
(±)-tert-Butyl 2-(naphthalen-2-ylmethyl)pyrrolidine-1-carboxylate (III-2c). General 
procedure 1 was employed for the coupling of 2-chloronapthalene (98 mg, 0.60 mmol) with tert-
butyl pent-4-en-1-ylcarbamate (93 mg, 0.50 mmol) to afford 126 mg (81%) of the title 
compound as a pale yellow oil. Spectroscopic properties were consistent with those reported in 
the literature.38 
 
(±)-tert-Butyl 2-[(1-benzyl-1H-indol-5-yl)methyl]pyrrolidine-1-carboxylate (III-2d). General 
procedure 1 was employed for the coupling of 1-benzyl-5-chloro-1H-indole (145 mg, 0.60 
mmol) with tert-butyl pent-4-en-1-ylcarbamate (93 mg, 0.50 mmol) to afford 125 mg (64%) of 
the title compound as an orange oil. 1H NMR (400 MHz, C6D5CD3, 100 °C) δ 7.46 (s, 1 H), 
7.04–7.01 (m, 2 H), 6.97–6.95 (m, 3 H), 6.84 (d, J = 7.0 Hz, 2 H), 6.73 (d, J = 2.9 Hz, 1 H), 6.42 
(d, J = 2.9 Hz, 1 H), 4.79 (s, 2 H), 4.13–4.04 (m, 1 H), 3.36–3.24 (m, 2 H), 3.24–3.16 (m, 1 H), 








NMR (100 MHz, C6D5CD3, 100 °C) δ 154.3, 138.2, 136.1, 130.9, 130.0, 128.2, 127.6, 127.1, 
124.0, 122.0, 121.8, 109.7, 102.1, 78.4, 59.6, 40.2, 46.9, 40.8, 30.0, 28.7, 23.4; IR (film) 1689, 
1395, 1171 cm–1; MS (ESI): 413.2191 (413.2205 calcd for C25H30N2O2, M + Na+). 
 
(±)-tert-Butyl 2-(2-chlorobenzyl)pyrrolidine-1-carboxylate (III-2e). General procedure 1 was 
employed for the coupling of 1,2-dichlorobenzene (80 µL mg, 0.60 mmol) with tert-butyl pent-
4-en-1-ylcarbamate (93 mg, 0.50 mmol) to afford 107 mg (73%) of the title compound as a pale 
yellow oil. 1H NMR (400 MHz, C6D5CD3, 100 °C) δ 7.14 (d, J = 8.0 Hz, 1 H), 7.09 (d, J = 7.4 
Hz, 1 H), 6.88 (t, J = 7.4 Hz, 1 H), 6.79 (t, J = 7.6, 1 H), 4.16–4.08 (m, 1 H), 3.34–3.24 (m, 1 H), 
3.23–3.12 (m, 2 H), 2.77 (dd, J = 8.6, 13.1 Hz, 1 H), 1.55–1.36 (m, 13 H); 13C NMR (100 MHz, 
C6D5CD3, 100 °C) δ 154.2, 137.9, 135.0, 132.0, 129.8, 126.8, 78.6, 58.2, 58.1, 46.6, 37.4, 29.9, 
28.7, 23.4; IR (film) 1692, 1393, 1172 cm–1; MS (ESI): 318.1224 (318.1237 calcd for 
C16H22ClNO2 M + Na+). 
 
(±)-tert-Butyl 2-(4-benzoylbenzyl)-4,4-dimethylpyrrolidine-1-carboxylate (III-2f). General 
procedure 1 was employed for the coupling of 4-chlorobenzophenone (130 mg, 0.60 mmol) with 
tert-butyl (2,2-dimethylpent-4-en-1-yl)carbamate (107 mg, 0.50 mmol) to afford 137 mg (70%) 
of the title compound as a pale yellow oil. 1H NMR (400 MHz, C6D5CD3, 100 °C) δ 7.85–7.75 
(m, 4 H), 7.35–7.17 (m, 5 H), 4.26–4.13 (m, 1 H), 3.58–3.43 (m, 2 H), 2.90 (d, J = 10.7 Hz, 1 H), 








H); 13C NMR (100 MHz, C6D5CD3, 100 °C) δ 195.2, 155.2, 144.5, 139.4, 137.0, 132.1, 131.9, 
79.3, 60.5, 59.2, 46.1, 41.8, 37.5, 29.1, 26.8, 26.6, 26.4 (two signals are missing due to incidental 
equivalence); IR (film) 1694, 1661, 1397, 1164 cm-1; MS (ESI): 416.2192 (416.2202 calcd for 
C25H31NO3 M + Na+). 
 
(±)-tert-Butyl 4,4-dimethyl-2-(naphthalen-1-ylmethyl)pyrrolidine-1-carboxylate (III-2g). 
General procedure 1 was employed for the coupling of 1-chloronaphthalene (82 µL, 0.60 mmol) 
with tert-butyl (2,2-dimethylpent-4-en-1-yl)carbamate (107 mg, 0.50 mmol) to afford 141 mg 
(83%) of the title compound as a pale yellow oil. 1H NMR (400 MHz, C6D5CD3, 100 °C) δ 8.55 
(s, br, 1 H), 7.66–7.52 (m, 2 H), 7.41–7.31 (m, 1 H), 7.28–7.14 (m, 3 H), 4.36–4.26 (m, 1 H), 
4.21–4.09 (m, 1 H), 2.91 (d, J = 10.7 Hz, 1 H), 2.72 (dd, J = 9.9, 12.8 Hz, 1 H), 1.51 (s, 9 H), 
1.40–1.22 (m, 2 H), 0.82 (s, 3 H), 0.68 (s, 3 H); 13C NMR (100 MHz, C6D5CD3, 100 °C) δ 155.2, 
136.0, 134.8, 133.4, 128.9, 127.3, 126.1, 125.1, 124.8, 79.0, 60.2, 58.2, 46.2, 39.3, 37.2, 28.8, 
26.4 (3 signals are missing due to incidental equivalence); IR (film) 1684, 1396, 1164 cm–1; MS 
(ESI): 362.2082 (362.2096 calcd for C22H29NO2, M + Na+). 
 
(±)-tert-Butyl 4,4-dimethyl-2-(pyridin-2-ylmethyl)pyrrolidine-1-carboxylate (III-2h). 
General procedure 1 was employed for the coupling of 2-chloropyridine (57 µL, 0.60 mmol) 
with tert-butyl (2,2-dimethylpent-4-en-1-yl)carbamate (107 mg, 0.50 mmol) to afford 107 mg 






(d, J = 4.5 Hz, 1 H), 7.12 (t, J = 7.6 Hz, 1 H), 6.98–6.94 (m, 1 H), 6.69–6.65 (m, 1 H), 4.28 (dq, 
J = 3.5, 8.2 Hz, 1 H), 3.53 (dd, J = 3.0, 13.0 Hz, 1 H), 3.36 (d, J = 10.4 Hz, 1 H), 2.91 (dd, J = 
8.9, 12.8 Hz, 1 H), 2.76 (d, J = 10.8 Hz, 1 H), 1.71–1.51 (m, 2 H), 1.46 (s, 9 H), 0.83 (s, 3 H), 
0.79 (s, 3 H); 13C NMR (100 MHz, C6D5CD3, 100 °C) δ 160.3, 154.8, 149.4, 135.5, 123.7, 120.8, 
78.6, 60.1, 58.0, 45.8, 43.4, 37.1, 28.7, 26.7, 26.1; IR (film) 1694, 1398, 1165 cm–1; MS (ESI): 
313.1890 (313.1892 calcd for C19H26N2O2, M + Na+). 
 
(±)-tert-Butyl 3-[4-(trifluoromethyl)benzyl]-2-azaspiro[4.5]decane-2-carboxylate (III-2i). 
General procedure 1 was employed for the coupling of 4-chlorobenzotrifluoride (80 µL, 0.60 
mmol) with tert-butyl [(1-allylcyclohexyl)methyl]carbamate (127 mg, 0.50 mmol) to afford 132 
mg (67%) of the title compound as a pale yellow oil. 1H NMR (400 MHz, C6D5CD3, 100 °C) δ 
7.36 (d, J = 7.8 Hz, 2 H), 7.07 (d, J = 7.6 Hz, 2 H), 3.97 (dq, J = 3.7, 8.0 Hz, 1 H), 3.55 (d, J = 
11.5 Hz, 1 H), 3.22 (dd, J = 2.7, 12.9 Hz, 1 H), 2.69 (d, J = 11.0 Hz, 1 H), 2.59 (dd, J = 8.7, 13.0 
Hz, 1 H), 1.58–1.50 (m, 1 H), 1.46 (s, 9 H), 1.23–1.10 (m, 11 H); 13C NMR (100 MHz, C6D5CD3, 
100 °C) δ 158.8, 144.1, 130.2, 125.4, 79.3, 58.3, 42.4, 41.7, 37.0, 35.2, 29.0, 26.8, 24.4, 23.5, 
21.4 (2 signals are missing due to incidental equivalence, and the CF3 quartet is obscured by the 
nmr solvent); IR (film) 1694, 1398, 1325 cm–1; MS (ESI): 420.2118 (420.2126 calcd for 










(±)-tert-Butyl 4,4-diallyl-2-(pyrazin-2-ylmethyl)pyrrolidine-1-carboxylate (III-2j). General 
procedure 1 was employed for the coupling of chloropyrazine (54 µL, 0.60 mmol) with tert-butyl 
(2,2-diallylpent-4-en-1-yl)carbamate (133 mg, 0.50 mmol) to afford 93 mg (54%) of the title 
compound as a pale yellow oil. 1H NMR (400 MHz, C6D5CD3, 100 °C) δ 8.35 (s, 1 H), 8.11–
8.03 (m, 2 H), 5.66–5.47 (m, 2 H), 4.96–4.83 (m, 4 H), 4.23–4.15 (m, 1 H), 3.51 (d, J = 11.0 Hz, 
1 H), 3.29 (dd, J = 3.5, 13.3 Hz, 1 H), 2.87 (dd, J = 8.2, 12.9 Hz, 1 H), 2.71 (d, J = 11.4 Hz, 1 H), 
1.88 (t, J = 6.3 Hz, 4 H), 1.71–1.63 (m, 1 H), 1.60–1.52 (m, 1 H), 1.43 (s, 9 H); 13C NMR (100 
MHz, C6D5CD3, 100 °C) δ 155.4, 154.5, 145.9, 143.3, 142.5, 134.6, 118.0, 117.8, 117.5, 117.2, 
79.0, 57.0, 55.9, 44.0, 41.8, 41.4, 40.6, 28.6; IR (film) 1694, 1398, 1160 cm–1; MS (ESI): 
366.2151 (366.2157 calcd for C20H29N3O2). 
 
(±)-(2S*,3R*)-tert-Butyl 3-methyl-2-(4-methylbenzyl)pyrrolidine-1-carboxylate (III-2k). 
General procedure 1 was employed for the coupling of 4-chlorotoluene (36 µL, 0.30 mmol) with 
(±)-tert-butyl (3-methylpent-4-en-1-yl)carbamate (50 mg, 0.25 mmol). Analysis of the crude 
reaction mixture indicated the product was formed with 4:1 d.r. as judged by 1H NMR analysis. 
Upon purification, 41 mg (57%) of the title compound was obtained as a yellow oil with 4:1 d.r. 
Data are for the major diastereomer.  1H NMR (400 MHz, C6D5CD3, 100 °C) δ 7.05–7.00 (m, 2 
H), 6.95–6.91 (m, 2 H), 3.65–3.58 (m, 1 H), 3.49–3.40 (m, 1 H), 3.11–2.98 (m, 2 H), 2.72–2.61 
(m, 1 H), 2.12 (s, 3 H), 1.92–1.83 (m, 1 H), 1.52–1.46 (m, 10 H), 1.12–1.02 (m, 1 H), 0.67 (d, J 
= 6.9 Hz, 3 H); 13C NMR (100 MHz, C6D5CD3, 100 °C) δ 154.4, 136.6, 135.5, 129.7, 129.0, 78.5, 
66.4, 45.6, 37.2, 31.4, 28.7, 20.8, 19.3, 19.2; IR (film) 1694, 1394, 1177 cm–1; MS (ESI): 






(III-2l). General procedure 1 was employed for the coupling of 4-chlorobenzotrifluoride (40 µL, 
0.30 mmol) with (±)-tert-butyl (3-phenylpent-4-en-1-yl)carbamate (65 mg, 0.25 mmol). Analysis 
of the crude reaction mixture indicated the product was formed with >20:1 d.r. as judged by 1H 
NMR analysis. Upon purification, 68 mg (67%) of the title compound was obtained as a pale 
yellow oil with >20:1 d.r. 1H NMR (400 MHz, C6D5CD3, 100 °C) δ 7.30 (d, J = 8.0 Hz, 2 H), 
7.05–7.00 (m, 3 H), 6.98–6.91 (m, 2 H), 6.84 (d, J = 7.4 Hz, 2 H), 4.19–4.12 (m, 1 H), 3.63–3.54 
(m, 1 H), 3.08–2.92 (m, 2 H), 2.89–2.79 (m, 2 H), 1.78–1.68 (m, 1 H), 1.61–1.51 (m, 1 H), 1.45 
(s, 9 H); 13C NMR (100 MHz, C6D5CD3, 100 °C) δ 154.2, 143.5, 143.2, 130.3, 127.1, 126.7, 
126.4, 79.2, 65.1, 49.1, 42.3, 39.6, 32.5, 28.6 (two signals are missing due to incidental 
equivalence, and the CF3 quartet is obscured by the nmr solvent); IR (film) 1692, 1394, 1325 
cm–1; MS (ESI): 428.1804 (428.1813 calcd for C23H26F3NO2, M + Na+). 
 
(±)-(2S*,3S*)-tert-Butyl 2-(3-methoxybenzyl)-3-phenylpyrrolidine-1-carboxylate (III-2m). 
General procedure 1 was employed for the coupling of 3-chloroanisole (37 µL, 0.30 mmol) with 
(±)-tert-butyl (3-phenylpent-4-en-1-yl)carbamate (65 mg, 0.25 mmol). Analysis of the crude 
reaction mixture indicated the product was formed with >20:1 d.r. as judged by 1H NMR 
analysis. Upon purification, 57 mg (62%) of the title compound was obtained as a pale yellow oil 









6.63 (dd, J = 2.2, 8.2 Hz, 1 H), 4.25–4.20 (m, 1 H), 3.65–3.56 (m, 1 H), 3.44 (s, 3 H), 3.17–3.08 
(m, 1 H), 3.06–2.86 (m, 3 H), 1.85–1.74 (m, 1 H), 1.63–1.53 (m, 1 H), 1.47 (s, 9 H); 13C NMR 
(100 MHz, C6D5CD3, 100 °C) δ 160.6, 154.2, 144.3, 140.6, 129.3, 129.0, 127.2, 126.5, 122.6, 
116.2, 112.6, 78.9, 65.5, 54.9, 48.5, 46.4, 39.9, 32.2, 28.7; IR (film) 1690, 1394 cm–1; MS (ESI): 
390.2044 (390.2045 calcd for C23H29NO3, M + Na+). 
 
(±)-(2R*,5R*)-tert-Butyl 2-methyl-5-(3-methylbenzyl)pyrrolidine-1-carboxylate (III-2n). 
General procedure 1 was employed for the coupling of 3-chlorotoluene (71 µL, 0.60 mmol) with 
(±)-tert-butyl hex-5-en-2-ylcarbamate (100 mg, 0.50 mmol). Analysis of the crude reaction 
mixture indicated the product was formed with >20:1 d.r. as judged by 1H NMR analysis. Upon 
purification, 105 mg (72%) of the title compound was obtained as a pale yellow oil with >20:1 
d.r. 1H NMR (400 MHz, C6D5CD3, 100 °C) δ 7.07–7.00 (m, 1 H), 6.99–6.95 (m, 1 H), 6.93 (d, J 
= 7.6 Hz, 1 H), 6.85 (d, J = 7.4 Hz, 1 H), 4.03–3.95 (m, 1 H), 3.80 (qt, J = 6.2, 6.4 Hz, 1 H), 3.14 
(dd, J = 3.8, 13.1 Hz, 1 H), 2.54 (dd, J = 9.0, 13.2 Hz, 1 H), 2.16 (s, 3 H), 1.64–1.43 (m, 12 H), 
1.31–1.20 (m, 1 H), 1.10 (d, J = 6.0 Hz, 3 H); 13C NMR (100 MHz, C6D5CD3, 100 °C) δ 154.6, 
139.8, 137.7, 130.7, 129.0, 127.7 127.1, 78.5, 60.7, 54.7, 42.2, 32.0, 28.8, 28.7, 21.9, 21.2; IR 
(film) 1692, 1390, 1177 cm–1; MS (ESI): 312.1945 (312.1939 calcd for C18H27NO2, M + Na+). 
 
(±)-(2R*,5R*)-tert-Butyl 2-(2-methoxybenzyl)-5-methylpyrrolidine-1-carboxylate (III-2o). 
General procedure 1 was employed for the coupling of 2-chloroanisole (76 µL, 0.60 mmol) with 







mixture indicated the product was formed with >20:1 d.r. as judged by 1H NMR analysis. Upon 
purification, 108 mg (71%) of the title compound was obtained as a pale yellow oil with >20:1 
d.r.  1H NMR (400 MHz, C6D5CD3, 100 °C) δ 7.12 (d, J = 7.3 Hz, 1 H), 7.03–6.98 (m, 1 H), 6.77 
(t, J = 7.3 Hz, 1 H), 6.60 (d, J = 8.1 Hz, 1 H), 4.19–4.12 (m, 1 H), 3.87–3.79 (m, 1 H), 3.46 (s, 3 
H), 3.18 (dd, J = 4.8, 13.1 Hz, 1 H), 2.78 (dd, J = 8.8, 13.0 Hz, 1 H), 1.71–1.56 (m, 2 H), 1.53–
1.31 (m, 11 H), 1.19 (d, J = 6.4 Hz, 3 H); 13C NMR (100 MHz, C6D5CD3, 100 °C) δ 158.6, 154.6, 
131.8, 131.7, 127.4, 120.8, 111.1, 78.3, 59.8, 55.0, 54.7, 35.9, 32.2, 29.0, 28.7, 22.1; IR (film) 
1693, 1390, 1364 cm–1; MS (ESI): 328.1886 (328.1889 calcd for C18H27NO3, M + Na+). 
 
(±)-1-Benzyl-3-(4-methoxyphenyl)-4-(2-methylbenzyl)imidazolidin-2-one (III-3).39 General 
procedure 1 was employed for the coupling of 2-chlorotoluene (70 µL, 0.60 mmol) with 1-allyl-
1-benzyl-3-(4-methoxyphenyl)urea (148 mg, 0.50 mmol) to afford 145 mg (75%) of the title 
compound as a yellow oil. Spectroscopic properties were consistent with those reported in the 
literature.39 
 
(±)-(3S*,5S*)-tert-Butyl 3-benzyl-5-phenylisoxazolidine-2-carboxylate (III-4).40 General 
procedure 1 was employed for the coupling of chlorobenzene (61 µL, 0.60 mmol) with (±)-tert-
butyl (1-phenylbut-3-en-1-yl)oxycarbamate (132 mg, 0.50 mmol). Analysis of the crude reaction 









purification 133 mg (78%) of the title compound was obtained as a pale yellow oil with 20:1 d.r. 
Spectroscopic properties were consistent with those reported in the literature.40 
 
(±)-tert-Butyl 5-(4-benzoylbenzyl)-3,3-dimethylpyrazolidine-1-carboxylate (III-5). General 
procedure 1 was employed for the coupling of 4-chlorobenzophenone (130 mg, 0.60 mmol) with 
tert-butyl 2-(2-methylpent-4-en-2-yl)hydrazinecarboxylate (107 mg, 0.50 mmol) to afford 144 
mg (73%) of the title compound as a yellow oil. 1H NMR (400 MHz, CDCl3) δ 7.80–7.72 (m, 4 
H), 7.61–7.55 (m, 1 H), 7.51–7.44 (m, 2 H), 7.29 (d, J = 8.0 Hz, 2 H), 4.35 (s, br, 1 H), 3.60 (s, 
br, 1 H), 3.18 (dd, J = 4.1, 12.9 Hz, 1 H), 2.80 (dd, J = 8.4, 12.9 Hz, 1 H), 1.99 (dd, J = 7.6, 12.3 
Hz, 1 H), 1.57–1.41 (m, 10 H), 1.17 (s, 3 H), 0.99 (s, 3 H); 13C NMR (100 MHz, CDCl3) δ 196.4, 
143.4, 137.7, 135.8, 132.2, 130.3, 129.9, 129.4, 128.3, 80.2, 60.9, 60.0, 47.1, 41.0, 28.5, 25.1, 
24.7 (one signals is missing due to incidental equivalence); IR (film) 3251, 1713, 1659 cm–1; MS 
(ESI): 417.2144 (417.2154 calcd for C24H30N2O3, M + Na+). 
 
(±)-2,2-Dimethyl-5-(naphthalen-1-ylmethyl)tetrahydrofuran (III-6).42 General procedure 1 
was employed for the coupling of 1-chloronapthalene (82 µL, 0.60 mmol) with 2-methylhex-5-
en-2-ol (57 mg, 0.50 mmol) to afford 107 mg (89%) of the title compound as a 13:1 mixture of 









Enantioconvergent Total Synthesis of (+)-Aphanorphine 
4.1 Introduction 
 The natural product (-)-aphanorphine (IV-1) was isolated in 1988 from the blue-green 
alga Aphanizomenon flos-aquae by Shimizu and Clardy.48 Although the biological activity of 
IV-1 has not been fully established, IV-1 shares common structural features with other 
benzomorphane analogues (Figure 4), several of which possess analgesic activity. Because of 
this unique structure, aphanorphine has been the subject of several total synthesis projects over 
the past several years.49,50  
Figure 4. Select Benzomorphane Alkaloids. 
 
 While both the natural and unnatural enantiomers of IV-1 have been prepared, many 
approaches have relied on chiral pool strategies. As such, the choice of target enantiomer must 
be determined early on in the synthesis. We felt we could develop an alternative route to IV-1 
whereby a simple racemic starting material could be converted to an enantiomerically-enriched 
precursor via an enantioselective Pd-catalyzed carboamination reaction developed in our 
laboratory.51 This synthetic route would represent a unique approach to natural products, as few 
natural product syntheses have been reported that employ a C–C bond-forming 
enantioconvergent step. 52  Additionally, most enantioconvergent strategies rely on kinetic 
resolution methods to facilitate separation of the two enantiomers, whereas our strategy would 



















4.2 Retrosynthetic Analysis 
 All of the work described in this chapter was carried out in close collaboration with Peter 
Mai, a graduate student in our group. Our approach to IV-1 would rely on two key 
transformations: an intramolecular Friedel-Crafts alkylation similar to that used in a few previous 
aphanorphine syntheses, and an enantioselective carboamination reaction of racemic starting 
material. As shown in Scheme 6, a catalyst-controlled asymmetric carboamination reaction of 
racemic substrate IV-5 could be used to set the C2 stereocenter of pyrrolidine IV-6, thereby 
providing a mixture of enantiomerically-enriched diastereomers. This mixture of diastereomers 
could be converted to a single enantiomerically-enriched stereoisomer IV-7 via a Friedel-Crafts 
alkylation, which would proceed through a carbocation intermediate IV-8. 
Scheme 6. Enantioconvergent Approach to (+)-Aphanorphine. 
 
 This approach overcomes several limitations of previous syntheses of IV-1. For example, 
either enantiomer of IV-1 could be accessed, because the absolute stereochemistry of the 
carboamination reaction would be dictated by the selection of an appropriate ligand. 53 






























and selection of a modified aryl halide in the carboamination step would afford a pyrrolidine that 
would be potentially useful for generating analogues of IV-1. 
4.3 Total Synthesis of (+)-Aphanorphine 
 The precursor for the key asymmetric carboamination reaction was prepared in four steps 
as shown in Scheme 7. Oxidation of N-Boc-1-amino-2-propanol to ketone IV-9 was 
accomplished in 97% yield using PCC. Grignard addition of allylmagnesium bromide afforded 
tertiary alcohol IV-10 in 92% yield, and protection in neat TMS-imidazole gave the 
carboamination substrate IV-11 in 91% yield. Of note, all of these steps can be performed on 
multi-gram scale without chromatography. 
Scheme 7. Synthesis of Carboamination Substrate. 
 
Previous studies on the Pd-catalyzed carboamination reaction have illustrated that 
diastereoselectives are generally low with substrates bearing a single homoallylic substituent, 
and the similarity in size of the homoallylic groups in IV-11 (CH3 vs. OTMS) suggested that 
there would be little substrate bias toward either diastereomer. We were pleased to see that 
exposure of IV-11 to previously reported conditions for enantioselective alkene carboamination 
reactions using (R)-Siphos-PE as a ligand proceeded in 75% yield to afford a 1:1 mixture of 















Scheme 8. Pd-Catalyzed Carboamination of IV-11 and Attempted Preparation of IV-13. 
 
Unfortunately, extensive attempts to effect the transformation of these diastereomers to 
tricycle IV-13 were unsuccessful. Additionally, cleavage of the O-TMS group using TBAF and 
subjecting the resulting alcohol to various conditions predominantly resulted in substrate 
decomposition. Competing cleavage of the Boc group was frequently observed, along with the 
formation of numerous side products and minimal product formation. Although we were unable 
to access intermediate IV-13, IV-14 has previously served as an intermediate in total syntheses 
of aphanorphine. Treatment of IV-12a and IV-12b with excess TFA in CH2Cl2 cleanly 
deprotected both the N-Boc and O-TMS groups, and tosylation of the resulting pyrrolidine 
derivative provided IV-15 as a 1:1 mixture of diastereomers (Scheme 9). 
 Intramolecular Friedel-Crafts alkylation of substrate IV-15 using AlCl3 provided tricycle 
IV-14 in 63% yield. IV-14 was found to be 81% e.e. by HPLC analysis. Subsequent removal of 
the N-tosyl group with Red-Al followed by N-methylation using Eschweiler-Clarke conditions 
provided IV-16. Although BBr3-mediated demethylation of IV-16 has been previously reported, 
this step proved to be quite challenging.55 Careful temperature control of the reaction mixture 
was required to obtain satisfactory results, and gradual warming from -30 °C to 0 °C in 10 °C 
increments over the course of 2 hours enabled the transformation of IV-16 to (+)-aphanorphine 
in 63% yield (Scheme 9).  
IV-11
4-bromoanisonle
2 mol % Pd2(dba)3
6 mol % (R)-Siphos-PE



















Scheme 9. Completion of the Total Synthesis of (+)-Aphanorphine. 
 
4.4 Conclusions 
 In conclusion, we have demonstrated an enantioconvergent total synthesis of (+)-
aphanorphine with the key step being an asymmetric Pd-catalyzed carboamination reaction. This 
synthesis relies on the conversion of a racemic starting material to an enantioenriched mixture of 
diastereomers, followed by the enantioconvergent formation of an all-carbon quaternary center 
through a Friedel-Crafts alkylation. Future studies will focus on the application of this approach 
to the synthesis of other benzomorphane analogues as well as the preparation of structural 































4.5 Experimental Section 
General: All reactions were carried out under a nitrogen atmosphere in flame-dried glassware. 
Tris(dibenzylideneacetone)dipalladium and (R)-Siphos-PE were purchased from Strem Chemical 
Co. and used without further purification. All reagents were obtained from commercial sources 
and were used as obtained. Toluene, THF, methylene chloride and diethyl ether were purified 
using a GlassContour solvent purification system. The yields reported in this section describe the 
result of a single experiment, whereas the yields reported in Schemes 7–9 are average yields of 
two or more experiments. Thus, the yields reported in this section may differ from those shown 
in Schemes 7–9. 
 
tert-Butyl (2-oxopropyl)carbamate (IV-9).56 A flame-dried flask was cooled under a stream of 
nitrogen and charged with pyridinium chlorochromate (12.3 g, 57 mmol) and CH2Cl2 (50 mL). 
The flask was cooled in an ice-water bath and (±)-tert-butyl (2-hydroxypropyl)carbamate (5.0 g 
in 10 mL CH2Cl2, 28.5 mmol) was added to the solution.  The resulting mixture was stirred 
overnight at rt, and Et2O (100 mL) was added to the system. The resulting black tar was filtered 
through a plug of silica gel and concentrated. The crude product was purified by flash 
chromatography on silica gel to afford 4.7 g (96%) of the title compound as a yellow oil. 
Spectroscopic properties were consistent with those reported in the literature.56  1H NMR (400 
MHz, CDCl3) δ 5.21 (s, br, 1 H), 4.03 (d, J = 4.5 Hz, 2 H), 2.18 (s, 3 H), 1.44 (s, 9 H). 
 
(±)-tert-Butyl (2-hydroxy-2-methylpent-4-en-1-yl)carbamate (IV-10).  A flame-dried flask 






(92 mL, 1 M in Et2O) and additional Et2O (25 mL). The resulting solution was cooled in an ice-
water bath, and a solution of tert-butyl (2-oxopropyl)carbamate (8.0 g, 46 mmol) in Et2O (25 
mL) was added slowly via syringe. The resulting mixture was warmed to rt and stirred until the 
starting material was consumed as judged by TLC analysis (ca. 1.5 h). The mixture was cooled 
in an ice-water bath, and the reaction was quenched by the slow addition of water (100 mL). The 
mixture was transferred to a separatory funnel, and the layers were separated. The aqueous layer 
was extracted with Et2O (2 x 100 mL), and the combined organic layers were dried over 
anhydrous Na2SO4, filtered and concentrated to afford 9.3 g (94%) of the title compound as a 
brown oil that was used without further purification. 1H NMR (500 MHz, CDCl3) δ 5.95–5.81 (m, 
1 H), 5.21–5.07 (m, 2 H), 4.90 (s, br, 1 H), 3.13 (d, J = 6.2 Hz, 2 H), 2.40 (s, 1 H), 2.23 (d, J = 
7.4 Hz, 2 H), 1.45 (s, 9 H), 1.16 (s, 3 H); 13C NMR (125 MHz, CDCl3) δ 156.7, 133.4, 118.3, 
79.1, 72.2, 49.6, 44.2, 28.1, 24.1; IR (film) 3369, 1694 cm-1; MS (ESI): 238.1417 (238.1419 calc 
for C11H21NO3, M + Na+). 
 
(±)-tert-Butyl {2-methyl-2-[(trimethylsilyl)oxy]pent-4-en-1-yl}carbamate (IV-11). A flame-
dried round bottom flask equipped with a stirbar was cooled under a stream of nitrogen and 
charged with  (±)-tert-butyl (2-hydroxy-2-methylpent-4-en-1-yl)carbamate (5.0 g, 23 mmol). 
Neat 1-(trimethylsilyl)-1H-imidazole (6.8 mL, 46 mmol) was added, and the resulting mixture 
was stirred at rt until the starting material had been consumed as judged by TLC analysis (ca. 4 
h). Water (10 mL) was added to the system and the resulting mixture was extracted with CH2Cl2 
(4 x 20 mL). The combined organic layers were dried over anhydrous Na2SO4, filtered and 
concentrated. The crude product was purified by flash chromatography on silica gel to afford 6.0 




1 H), 5.09–5.01 (m, 2 H), 4.74 (s, br, 1 H), 3.16–2.99 (m, 2 H), 2.23 (d, J = 7.2 Hz, 2 H), 1.45 (s, 
9 H), 1.19 (s, 3 H), 0.13 (s, 9 H). 13C NMR (100 MHz, CDCl3) δ 156.1, 133.9, 117.9, 79.0, 75.7, 
50.0, 45.2, 28.3, 24.9, 2.5; IR (film) 3368, 1720 cm-1; MS (ESI): 310.1815 (311.1833 calcd for 
C14H29NO3Si, M + Na+). 
 
 (+)-(2S,4RS)-tert-Butyl 2-(4-methoxybenzyl)-4-methyl-4-[(trimethylsilyl)oxy]pyrrolidine-1-
carboxylate (IV-12a-b). A flame-dried Schlenk tube was cooled under a stream of nitrogen and 
charged with Pd2(dba)3 (191 mg, 0.2 mmol), (R)-Siphos-PE (303 mg, 0.06 mmol) and NaOtBu 
(960 mg, 0.5 mmol). The tube was evacuated and backfilled with nitrogen three times, then a 
solution of (±)-tert-butyl {2-methyl-2-[(trimethylsilyl)oxy]pent-4-en-1-yl}carbamate (3.0 g, 10 
mmol) and 4-bromoanisole (3.74 g, 20 mmol) in toluene (30 mL) was added via syringe. The 
resulting mixture was stirred at rt for 1 min then was immersed in 90 °C oil bath and stirred 
overnight (ca 14 h). The mixture was then cooled to room temperature and saturated aqueous 
ammonium chloride (10 mL) was added. The mixture was transferred to a separatory funnel, the 
layers were separated, and the aqueous layer was extracted with EtOAc (3 x 30 mL). The 
combined organic layers were dried over anhydrous Na2SO4, filtered, and concentrated. The 
crude product was purified by flash chromatography on silica gel to afford 3.1 g (75%) of the 
title compound as a pale yellow oil. The product was judged to be a 1:1 mixture of rotamers and 
a 1:1 mixture of diastereomers by 1H NMR analysis. Data are for the mixture. [a]23D +18.4 (c 1.0, 
CH2Cl2); 1H NMR (400 MHz, CDCl3) δ 7.17–7.03 (m, 2 H), 6.86–6.78 (m, 2 H), 4.19–3.82 (m, 1 
H), 3.79 (s, 3 H), 3.76–3.10 (m, 2 H), 2.93–2.54 (m, 2 H), 1.94–1.79 (m, 1 H), 1.77–1.66 (m, 1 









CDCl3) δ 157.8, 157.7, 154.9, 154.7, 154.3, 130.8, 130.5, 130.3, 130.2, 130.0, 126.5, 113.6, 
113.5, 113.4, 113.3, 79.0, 78.9, 78.8, 78.6, 78.0, 77.8, 77.6, 59.9, 59.7, 59.1, 59.0, 58.8, 58.2, 
57.9, 54.7, 46.6, 45.5, 44.5, 43.4, 39.6, 39.4, 38.3, 38.2, 28.3, 28.1, 28.0, 26.6, 26.5, 24.8, 24.7, 
2.2, 1.9, 1.8, 1.7; IR (film) 2972, 1699, 1684 cm-1; MS (ESI): 416.2228 (416.2233 calcd for 
C21H35NO4Si, M + Na+). 
 
(+)-(5S,3RS)-5-(4-Methoxybenzyl)-3-methyl-1-tosylpyrrolidin-3-ol (IV-15). 57  A round-
bottom flask equipped with a stirbar was charged with (+)-(2S,4RS)-tert-butyl 2-(4-
methoxybenzyl)-4-methyl-4-[(trimethylsilyl)oxy]pyrrolidine-1-carboxylate and CH2Cl2 (7.6 mL). 
The resulting solution was cooled to 0 °C, trifluoroacetic acid (5.7 mL, 76.2 mmol) was added to 
the system, and the solution was warmed to rt and stirred until the starting material had been 
consumed as judged by TLC analysis (ca. 10 min). The reaction mixture was diluted with water, 
basified with aqueous NH4OH and transferred to a separatory funnel. The layers were separated 
and the aqueous layer was extracted with CH2Cl2 (3 x 50 mL). The combined organic layers 
were dried over anhydrous Na2SO4, filtered and concentrated. The crude product was dissolved 
in THF (5 mL) and the resulting solution was added to a stirring solution of triethylamine (3.2 
mL, 22.9 mmol), tosyl chloride (2.18 mg, 11.4 mmol) and THF (10 mL). The reaction mixture 
was stirred overnight at rt, and saturated aqueous NaHCO3 (10 mL) was added to the system. 
The mixture was transferred to a separatory funnel and extracted with CH2Cl2 (3 x 50 mL). The 
combined organic layers were dried over anhydrous Na2SO4, filtered and concentrated. The 
crude product was purified by flash chromatography on silica gel to afford 2.3 g (80%) of the 









by 1H NMR analysis. Data are for the mixture. [a]23D +65.7 (c 1.0, CH2Cl2); 1H NMR (400 MHz, 
CDCl3) δ 7.82–7.73 (m, 2 H), 7.36–7.30 (m, 2 H), 7.20 (d, J = 8.0 Hz, 1.2 H), 7.14 (d, J = 8.4 Hz, 
0.8 H), 6.88–6.80 (m, 2 H), 4.02–3.94 (m, 0.5 H), 3.83–3.75 (m, 3.5 H), 3.42–3.37 (m, 1 H), 
3.30–3.21 (m, 1 H), 3.18–3.07 (m, 1 H), 3.03 (d, J = 10.4 Hz, 0.6 H), 2.83 (dd, J = 9.2, 13.6 Hz, 
0.4 H), 2.44–2.41 (m, 3 H), 1.84–1.74 (m, 1 H), 1.64–1.54 (m, 2 H), 1.19 (m, 1 H), 1.09 (s, 2 H); 
13C NMR (100 MHz, CDCl3) δ 158.3, 143.7, 143.6, 133.9, 130.9, 130.6, 130.0, 129.8, 129.7, 
129.6, 127.8, 127.7, 113.9, 113.7, 76.1, 76.0, 61.7, 61.6, 61.5, 61.0, 55.2, 45.5, 43.2, 41.1, 41.0, 
25.4, 24.1, 21.5 (5 peaks are incidentally equivalent).  
 
(+)-(1S,4S)-8-Methoxy-1-methyl-3-tosyl-2,3,4,5-tetrahydro-1H-1,4-methanobenzo[d]azepine 
(IV-14).58 A flame-dried round-bottom flask was charged with aluminum trichloride (8.0 g, 60 
mmol) and CH2Cl2 (100 mL). The flask was cooled to 0 °C, and a solution of (+)-(5S,3RS)-5-(4-
methoxybenzyl)-3-methyl-1-tosylpyrrolidin-3-ol (2.15 g, 5.7 mmol) in CH2Cl2 (20 mL) was 
added via syringe. The resulting mixture was allowed to slowly warm to rt and was stirred 
overnight. The reaction mixture was poured into a solution of saturated aqueous NaHCO3 (50 
mL). The mixture was transferred to a separatory funnel, the layers were separated and the 
aqueous layer was extracted with CH2Cl2 (2 x 50 mL). The combined organic layers were dried 
over anhydrous Na2SO4, filtered and concentrated. The crude product was purified by flash 
chromatography on silica gel to afford 1.2 g (60%) of the title compound as a pale yellow solid. 
The enantiomeric excess was determined to be 81% e.e. by chiral HPLC analysis (Chiralpak AD-
H 0.46 cm x 25 cm, 1 % iPrOH/hexanes, 1 mL/min, λ = 254 nm, major RT = 8.0, minor RT = 





[a]23D +16.0 (c 1.0, CH2Cl2) [for ent-13 lit.58 [α]27D –16.9 (c 0.89, CHCl3)]; mp: 137–140 °C 
(lit.58 mp 136–138 °C); 1H NMR (400 MHz, CDCl3) δ 7.70 (d, J = 8.4 Hz, 2 H), 7.28 (d, J = 8.0 
Hz, 2 H), 6.97 (d, J = 8.4 Hz, 1 H), 6.78 (d, J = 2.5 Hz, 1 H), 6.72 (dd, J = 2.6, 8.3 Hz, 1 H), 
4.41–4.35 (m, 1 H), 3.78 (s, 3 H), 3.40 (dd, J = 1.2, 8.7 Hz, 1 H), 3.11 (d, J = 16.6 Hz, 1 H), 3.02 
(d, J = 8.6 Hz, 1 H), 2.93 (dd, J = 2.8, 16.5 Hz, 1 H), 2.42 (s, 3 H), 1.79 (d, J = 11.5 Hz, 1 H), 
1.50–1.38 (m, 4 H). 
 
(+)- (1S,4S)-8-Methoxy-1-methyl-2,3,4,5-tetrahydro-1H-1,4-methanobenzo[d]azepine (IV-
S1). A flame-dried round-bottom flask was charged with (+)-(1S,4S)-8-methoxy-1-methyl-3-
tosyl-2,3,4,5-tetrahydro-1H-1,4-methanobenzo[d]azepine (1.1 g, 3.1 mmol) and xylene (15 mL). 
A solution of Red-Al was added (3.5 M in toluene, 3.3 mL, 11.4 mmol), and the mixture was 
heated at reflux for 1 h. The solution was cooled to 0 °C, diluted with ether and a few drops of 
water were added to the system. The solution was filtered through a pad of celite and 
concentrated in vacuo. The crude product was purified by flash chromatography on silica gel to 
afford 450 mg (71%) of the title compound as a yellow oil.  [a]23D +38.2 (c 1.0, CH2Cl2); 1H 
NMR (500 MHz, CDCl3) δ 7.02 (d, J = 8.5 Hz, 1 H), 6.82 (d, J = 2.5 Hz, 1 H), 6.71 (dd, J = 3.0, 
8.5 Hz, 1 H), 3.85–3.79 (m, 4 H), 3.11–3.02 (m, 2 H), 2.92 (d, J = 10 Hz, 1 H), 2.78 (m, 2 H), 
1.96–1.92 (m, 1 H), 1.86 (d, J = 11 Hz, 1 H), 1.49 (s, 3 H). 
 
(–)-8-O-Methylaphanorphine (IV-16). A flame-dried round-bottom flask was charged with (+)-








mmol), a solution of 37% aqueous formalin (1.8 mL) and formic acid (2.8 mL). The reaction 
mixture was heated at 100 °C for 1.5 h, cooled to rt, diluted with water (10 mL) and basified 
with 10% aqueous NaOH. The mixture was transferred to a separatory funnel and extracted with 
CH2Cl2 (3 x 20 mL). The combined organic layers were dried over anhydrous Na2SO4, filtered 
and concentrated in vacuo. The crude product was purified by flash chromatography on silica gel 
to afford 294 mg (90%) of the title compound as a pale yellow oil.  Spectroscopic properties 
were consistent with those previously reported in the literature. [a]23D –5.8 (c 1.0, CHCl3), [lit.59 
[α]27D –7.4 (c 0.35, CHCl3)]; 1H NMR (400 MHz, CDCl3) δ 7.02 (d, J = 8.4 Hz, 1 H), 6.78 (d, J 
= 2.8 Hz, 1 H), 6.68 (dd, J = 2.8, 8.4 Hz, 1 H), 3.78 (s, 3 H), 3.42 (m, 1 H), 3.02 (d, J = 16.4 Hz, 
1 H), 2.88–2.84 (m, 1 H), 2.82 (d, J = 1.2 Hz, 1 H), 2.76 (d, J = 9.2 Hz, 1 H), 2.48 (s, 3 H), 2.02 
(ddd, J = 1.2, 5.6, 10.8 Hz, 1 H), 1.48 (s, 3 H).   
 
(+)-Aphanorphine (IV-1). Demethylation of (–)-8-O-methylaphanorphine was carried out 
according to the reported procedure.60 A flame-dried round-bottom flask was charged with 15 
(40 mg, 0.18 mmol) and CH2Cl2 (1 mL) and cooled to –30 ˚C. BBr3 (1.0 M in CH2Cl2, 0.36 mL) 
was added slowly dropwise. The reaction mixture was stirred for 30 min at –30 ˚C, 30 min at –20 
˚C, 30 min at –10 ˚C and 30 min at 0 ˚C. The reaction was quenched at 0 °C with aqueous 
NaHCO3, and the mixture extracted with CH2Cl2 (3 x 5 mL). The combined organic layers were 
dried over anhydrous Na2SO4, filtered and concentrated in vacuo. The resulting residue was 
taken up in 2 mL of 3 M NaOH and heated at 100 °C for 5 min. The solution was acidified with 
1 M HCl and basified with saturated aqueous NaHCO3. The mixture was extracted with CH2Cl2 





was triturated with acetone to afford 23 mg (63%) of the title compound as a white solid. 
Spectroscopic properties were consistent with those present in the literature. [a]23D +28.0 (c 0.1, 
MeOH) [lit.59 [α]27D +37.5 (c 0.16, MeOH)]; mp 202–208 °C (lit.59 mp 215–222). 1H NMR (400 
MHz, CD3OD) δ 6.89 (d, J = 8 Hz, 1 H), δ 6.67 (d, J = 2.4 Hz, 1 H), δ 6.56 (dd, J = 2.4, 8.4 Hz, 
1 H), 3.38 (m, 1 H), 2.97 (d, J = 16.8 Hz, 1 H), 2.85 (m, 2 H), 2.63 (d, J = 9.6 Hz, 1 H), 2.40 (s, 
3 H), 2.01 (q, J = 5.6 Hz, 1 H), 1.83 (d, J = 11.2 Hz, 1 H), 1.44 (s, 3 H); 13C NMR (100 MHz, 
CD3OD) δ 156.6, 148.6, 131.2, 125.2, 114.5, 110.9, 72.7, 63.4, 44.3, 42.8, 42.1, 36.7, 21.7.   
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